Otros idiomas Biocon Limited

Acciones

BIOCON

INE376G01013

Diferido NSE India S.E. Otros sitios de cotización 07:44:48 22/05/2024			Varia. Cinco días.	Varia. 1 de enero.
309,1 ^INR	+0,49 %		-0,77 %	+23,97 %

17/05	BIOCON LIMITED : Jefferies & Co. reitera su recomendación de venta.	ZM
17/05	El beneficio neto consolidado de Biocon desciende en el cuarto trimestre fiscal	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Biocon's Consolidated Net Profit Declines in Fiscal Q4	17/05
India's Biocon posts Q4 profit fall as higher raw material costs bite	16/05
Biocon Limited Reports Earnings Results for the Full Year Ended March 31, 2024	16/05
Biocon Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	16/05
Biocon Limited signs semi-exclusive distribution and supply deal for the commercialization of generic Saxenda in Mexico with Medix	13/05
Biocon Signs Deal with Medix for Commercialization of Chronic Weight Management Drug in Mexico	13/05
Natural Biocon (India) CFO Passes Away	30/04
Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	20/04
India's Biocon developing its own version of Wegovy, clinical trial likely next year	18/04
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	18/04
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	17/04
Biocon Board to Consider Dividend for Fiscal 2024	11/04
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	01/04
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.	28/03
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	27/03
Updates On Aflibercept BPCIA Litigation	26/03
Biocon Limited Receives an Order from the Reserve Bank of India	22/03
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03
Biocon's CFO Resigns	15/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Biocon Limited

Acciones

BIOCON

INE376G01013

Otros idiomas

Filtros